Imaging Melphalan Therapy Response in Preclinical Extramedullary Multiple Myeloma with (18)F-FDOPA and (18)F-FDG PET

Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necess...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Nucl Med
Asıl Yazarlar: Hathi, Deep K., DeLassus, Elizabeth N., Achilefu, Samuel, McConathy, Jonathan, Shokeen, Monica
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Society of Nuclear Medicine 2018
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167538/
https://ncbi.nlm.nih.gov/pubmed/29700126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.208744
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller